Article
Approaches for the development of drugs for treatment of obesity and metabolic syndrome
Fecha
2016Registro en:
22, 7, 895-903
13816128
Autor
Maksimov M.L.
Svistunov A.A.
Tarasov V.V.
Chubarev V.N.
Ávila-Rodriguez M.
Barreto G.E.
Dralova O.V.
Aliev G.
Institución
Materias
Ítems relacionados
Mostrando ítems relacionados por Título, autor o materia.
-
Putative Role of the Aldo-Keto Reductase from Trypanosoma cruzi in Benznidazole Metabolism
Garavaglia, Patricia Andrea; Garavaglia, Patricia Andrea; Garavaglia, Patricia Andrea; Garavaglia, Patricia Andrea; Garavaglia, Patricia Andrea; Laverriere, Marc; Laverriere, Marc; Laverriere, Marc; Laverriere, Marc; Laverriere, Marc; Cannata, Joaquin Juan Bautista; Cannata, Joaquin Juan Bautista; Cannata, Joaquin Juan Bautista; Cannata, Joaquin Juan Bautista; Cannata, Joaquin Juan Bautista; Garcia, Gabriela Andrea; Garcia, Gabriela Andrea; Garcia, Gabriela Andrea; Garcia, Gabriela Andrea; Garcia, Gabriela Andrea (American Society for MicrobiologyAmerican Society for MicrobiologyAmerican Society for MicrobiologyAmerican Society for MicrobiologyAmerican Society for Microbiology, 2016-05)Benznidazole (Bz), the drug used for treatment of Chagas' disease (caused by the protozoan Trypanosoma cruzi), is activated by a parasitic NADH-dependent type I nitroreductase (NTR I). However, several studies have shown ... -
A circunferência do pescoço como marcador da resistência à insulina e síndrome metabólica : BRAMS: Brazilian Metabolic Syndrome Study
Stabe, Christiane França Camargo, 1973 -
Effects of short- and long-term Mediterranean-based dietary treatment on plasma LC-QTOF/MS metabolic profiling of subjects with metabolic syndrome features: The Metabolic Syndrome Reduction in Navarra (RESMENA) randomized controlled trial
Bondia-Pons I.; Martinez J.A.; de la Iglesia R.; Lopez-Legarrea P.; Poutanen K.; Hanhineva K.; Zulet M.D.L.A. (Wiley-VCH Verlag, 2015)